ThromboGenics' JETREA® Nominated for 2013 Prix Galien USA LEUVEN, Belgium, October 21, 2013 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR) a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces today that JETREA® (ocriplasmin) is nominated for the 2013 Prix Galien USA...
Oct. 21, 2013 - PR Newswire